Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Real-World Impact of UGT1A1 Genotype-Guided Irinotecan Dosing on Severe Toxicity and Hospitalization: A Multicenter Study.

Journal of the National Comprehensive Cancer Network : JNCCN - 11 Jun 2026

Heersche Niels, Peeters Sofía L J, Böhm Doortje, Böhringer Stefan, Guiljam Roselien, Hulshof Emma C, de Man Femke M, de With Mirjam, Joosse Marije, Oomens Gysella, Wu Qiong-Yi, Bins Sander, van Hellemond Irene E G, Haberkorn Brigitte C M, Verschoor Arjan J, Wumkes Miriam L, Thijs Anna M, van Schaik Ron H N, Gelderblom Hans, Guchelaar Henk-Jan, Mathijssen Ron H J, Deenen Maarten J

Abstract excerpt

BACKGROUND: Risk of irinotecan-related severe toxicity is significantly higher in patients carrying 2 dysfunctional UGT1A1 gene variants, characterized as poor metabolizers (PMs), following standard irinotecan dosing. Since 2020, we implemented UGT1A1 genotype-guided dosing of irinotecan in routine clinical practice to reduce toxicity in PMs. This study evaluates its impact on severe toxicity in a real-world...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotype

Share to Glucuronosyltransferase

Share to Hospitalization

Share to Irinotecan

Source

Identifiers

PMID: 42276133
DOI: 10.6004/jnccn.2026.7011

Genes

UGT1A1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Real-World Impact of UGT1A1 Genotype-Guided Irinotecan Dosing on Severe Toxicity and Hospitalization: A Multicenter Study.PMID 42276133Read ↗

UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients.Semantic proximity Read ↗

Pharmacogenetic-guided dosing for fluoropyrimidine (DPYD) and irinotecan (UGT1A1*28) chemotherapies for patients with cancer (PACIFIC-PGx): A multicenter clinical trial.Semantic proximity Read ↗

Efficacy and safety of high doses of irinotecan in patients with metastatic colorectal cancer treated with the FOLFIRI regimen based on the UGT1A1 genotype: A systematic review.Semantic proximity Read ↗

A single-arm phase II trial of UGT1A1 genotype–guided high-dose irinotecan rechallenge in refractory metastatic colorectal cancerSemantic proximity Read ↗

Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction between UGT1A1 and irinotecan.Semantic proximity Read ↗

Pre-therapeutic UGT1A1 genotyping to reduce the risk of irinotecan-induced severe toxicity: Ready for prime time.Semantic proximity Read ↗

Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan?Semantic proximity Read ↗

Elucidating the role of pharmacogenetics in irinotecan efficacy and adverse events in metastatic colorectal cancer patients.Semantic proximity Read ↗

Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses.Semantic proximity Read ↗

Impact of UGT1A1 genotype on the efficacy and safety of irinotecan-based chemotherapy in metastatic colorectal cancer.Semantic proximity Read ↗

Clinical observations on associations between the UGT1A1 genotype and severe toxicity of irinotecan.Semantic proximity Read ↗

Optimizing fluoropyrimidine therapy: Real‐world impact of DPYD genotype‐based dosing on severe toxicity ratesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.